Apteka Exhibition Russian Health Care Week UFI Approved Event
To main
For exhibitors
For visitors
Program
Contacts

Abbott’s fourth-quarter profit falls on pharmaceutical business separation costs

24.01.2013

Abbott has presented its fourth quarter results for 2012. The proprietary pharmaceutical sales were $5.1 billion, up 7.4%. Humira was a major contributor with sales coming in at $2.7 billion, up 23.1%. Fourth-quarter net income came in at $1.1 billion, down 34.9% because of costs related to spinoff of its AbbVie pharmaceutical business.

Fourth quarter sales rose 4.4% to $10.8 billion narrowly beating the analytical estimate of $10.6 billion. Full-year revenues increased 2.6% to $39.9 billion in 2012. Net income increased 26.1% to $6 billion. Total proprietary pharmaceutical sales were $18 billion, up 5.5% year on year. Humira sales rose 16.8% to $9.3 billion.

Source: pharmvestnik.ru


Back to the list


Invite partners to the exhibition
Facebook Youtube RSS Feed





Contacts Flashback Site map
119002 Moscow, Arbat str., 35, of. 423
Тel: +7 (495) 925-65-61/62
Fax: +7 (499) 248-07-34